Skip to main content
OpenTrials
Completed

NCT Number: NCT03658486

Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial

This feasibility study will investigate whether men with metastatic prostate cancer can take part in and progress through a home-based exercise program. This study will evaluate the effects of exercise on a range of disease and treatment-related outcomes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Metastatic Behavior Castration-resistant Prostate Cancer Motor Activity

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Northern Ireland Cancer Centre, Belfast City Hospital

Belfast, BT9 7JL, United Kingdom

About this study

This 12 week multicomponent, tailored, progressive program will consist of both moderate intensity walking and strengthening exercises at home. This single centre, single arm study will incorporate a behavioural change consultation at baseline and weekly behavioural support throughout. This study will follow-up patients at 24 weeks to determine exercise maintenance. Outcome measures will be completed at baseline, 12 and 24 weeks. A qualitative evaluation will be conducted after the 24 week follow-up to determine impact, patient experience and measures that might assist in refining the program.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histologically documented adenocarcinoma of the prostate with progressive systemic metastatic disease despite castrate levels of testosterone (<50ng/dL).
  • At enrolment, patients must have demonstrated progressive disease since the most recent change in therapy.
  • Patients must be on ADT with a GnRH agonist/antagonist or prior bilateral orchiectomy. All patients must be on ADT during the study period.
  • ≥ 4 weeks since last surgery and fully recovered.
  • No known contraindications to moderate intensity exercise such as (but not limited to) brain metastases, acute congestive heart failure, unstable angina, serious or non-healing wound, peripheral neuropathy greater than or equal to Grade 3. Recent myocardial infarction.
  • Age ≥ 18 years.
  • ECOG performance status 0-2.
  • Medical clearance by treating clinician.

Exclusion criteria

  • Men currently exceeding ACSM recommended exercise guidelines (150 mins of moderate and/or 60 mins of high intensity exercise per week).
  • Men with brain metastases.
  • Men with a currently active second malignancy other than non-melanoma skin cancer.
  • Congestive heart failure or recent serious cardiovascular event.
  • Chest pain brought on by physical activity.

Treatment and study plan

Exercise

Other

Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.

Primary outcomes

  1. Feasibility - recruitment.

    Time frame: At baseline.

    The number of participants that agree to participate or are excluded.

  2. Feasibility - adherence to the exercise intervention.

    Time frame: Throughout the 24 week study period.

    Determine the percentage of patients adhering to the program and the weekly behavioral consultation sessions.

  3. Feasibility - attrition rates.

    Time frame: Throughout the 24 week study period.

    The number of patients that withdraw.

  4. Feasibility - safety / adverse events.

    Time frame: Monitored throughout the 24 week study period.

    Any safety / adverse events, in general or in relation to the exercise program, will be documented by the research team.

  5. Feasibility - patient experience.

    Time frame: Following the study conclusion at 24 weeks.

    Determined by qualitative evaluation, using semi-structured interviews, to assess experiences, accessibility and acceptability of the exercise intervention.

Secondary outcomes

  1. Anthropometric assessment.

    Time frame: At baseline, 12 and 24 weeks.

    Height will be measured in cm and body weight in kg, which will be combined to report BMI in kg/m(squared).

  2. Hip and waist circumference analysis.

    Time frame: At baseline, 12 and 24 weeks.

    Hip and waist circumference will be measured in cms.

  3. Functional ability assessment.

    Time frame: At baseline, 12 and 24 weeks.

    The amount of repetitions achieved during a 30 second sit-to-stand test will be recorded.

  4. Physical fitness assessment.

    Time frame: At baseline, 12 and 24 weeks.

    Distance covered in meters during a six minute walk test will be recorded.

  5. Objectively measure of physical activity levels.

    Time frame: At baseline, 12 and 24 weeks.

    Patients will wear an accelerometer for 7 full days.

  6. Perceived physical activity levels.

    Time frame: At baseline, 12 and 24 weeks.

    Patients will complete an International Physical Activity Questionnaire (IPAQ-SF). This questionnaire will comprise 4 generic items to obtain comparable health-related physical activity. Patients will detail the number of days, hours and minutes that they undertake (1) vigorous exercise (2) moderate exercise (3) walking exercise and (4) sitting. Total physical activity will be generated and monitored for improvement or decline.

  7. Cancer-related fatigue by questionnaire.

    Time frame: At baseline, 12 and 24 weeks.

    Fatigue will be measured by the Functional Assessment of Cancer Therapy - Fatigue (FACIT-Fatigue) questionnaire. Patients will score several fatigue items over the past 7 days on a scale (0 = not at all; 4 = very much), generating a total (0 - 52) with higher scores linked to greater quality of life.

  8. Quality of life will be measured using a questionnaire.

    Time frame: At baseline, 12 and 24 weeks.

    Quality of life will be measured by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire. Patients will score a series of questions (0 = not at all; 4 = very much) in five sections (physical well-being; social/family well-being; emotional well-being; functional well-being; additional concerns) for the past 7 days. Higher scores will suggest better quality of life.

  9. Quality of life will be measured using questionnaires.

    Time frame: At baseline, 12 and 24 weeks.

    Quality of life will be measured by the EuroQOL Five Dimension Questionnaire (EQ5D). Patients will select a level of difficulty (I have no - I have extreme) on that particular days health for mobility, self-care, usual activities, pain / discomfort and anxiety / depression. Patients will then rate 'how good' or 'how bad' their health is on that day using a 100 point scale (0 = worst health you can imagine; 100 = best health you can imagine).

  10. Pain will be measured through a questionnaire.

    Time frame: At baseline, 12 and 24 weeks.

    Bone pain will be monitored using the Brief Pain Inventory Short Form (BPI-SF).

Sponsors and collaborators

Lead sponsor

Queen's University, Belfast

Other

Collaborators

  • HSC Public Health Agency

Registry information

Official study title

Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial in Men With Metastatic Castrate-Resistant Prostate Cancer

Acronym: EXACT

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Sep 5, 2018
Registry last updated
Feb 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.